102
Participants
Start Date
April 26, 2023
Primary Completion Date
January 2, 2024
Study Completion Date
November 2, 2024
Genicular nerve block with bupivacaine and corticosteroids
"\- GROUP 1:Genicular Nerve Block with Bupivacaine and Corticosteroids: 2.5 mL at three genicular nerve points.~All injections are ultrasound-guided and administered once. The primary outcome is pain reduction, measured using NRS, KOOS, WOMAC, and KUJALA scales at 4, 12, and 24 weeks post-injection. Follow-up includes phone and in-person consultations to monitor pain, functionality, and adverse effects."
Genicular nerve block with bupivacaine
"\- GROUP 2: Genicular Nerve Block with Bupivacaine: 2.5 mL at three genicular nerve points.~All injections are ultrasound-guided and administered once. The primary outcome is pain reduction, measured using NRS, KOOS, WOMAC, and KUJALA scales at 4, 12, and 24 weeks post-injection. Follow-up includes phone and in-person consultations to monitor pain, functionality, and adverse effects."
Genicular nerve block with saline
"\- GROUP 3: Genicular Nerve Block with Saline: 2.5 mL at three genicular nerve points.~All injections are ultrasound-guided and administered once. The primary outcome is pain reduction, measured using NRS, KOOS, WOMAC, and KUJALA scales at 4, 12, and 24 weeks post-injection. Follow-up includes phone and in-person consultations to monitor pain, functionality, and adverse effects."
Hospital Universitario Fundación Alcorcón, Alcorcón
Hospital Universitario Fundación Alcorcón
OTHER